Under the agreement, urologists will be able to order Mitomics’ PCMT kit, through LabCorp’s specialized laboratory subsidiary, DIANON systems, which focuses on anatomic pathology, including uropathology.
PCMT, which is based on the science of mitochondrial DNA (mtDNA), determines the presence of malignant cells of prostate gland via a cancerization field effect by detecting underlying molecular alterations in normal-appearing tissue.
Mitomics president and chief executive officer Robert Poulter said by collaborating with LabCorp and DIANON, the company can offer convenient ordering of and information about PCMT to its urology customers throughout the US.
"This agreement supports our commercial strategy to provide broad access to PCMT and further validates the strong demand from physicians to improve the diagnosis of prostate cancer for patients," Poulter added.